Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Cash Flows

v3.10.0.1
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows from Operating Activities:    
Net loss $ (24,748) $ (16,759)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 2,336 4,271
Issuance of common shares - Founders Agreement 815 0
Research and development-licenses acquired, expensed 0 400
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 661 (1,821)
Other receivables - related party 326 471
Accounts payable and accrued expenses 2,410 2,170
Net cash used in operating activities (18,200) (11,268)
Cash Flows from Investing Activities:    
Purchase of research and development licenses 0 (400)
Net cash used in investing activities 0 (400)
Cash Flows from Financing Activities:    
Issuance of common shares - Public offering 23,012 0
Offering costs for the issuance of common shares - Public offering (2,184) 0
Issuance of common shares - At-the-market offering 7,981 0
Offering costs for the issuance of common shares - At-the-market offering (234) 0
Net cash provided by financing activities 28,575 0
Net increase (decrease) in cash and cash equivalents 10,375 (11,668)
Cash and cash equivalents at beginning of period 19,225 35,086
Cash and cash equivalents at end of period 29,600 23,418
Supplemental disclosure of noncash investing and financing activities:    
Issuance of common shares - Founders Agreement $ 2,296 $ 3,919